• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Halitosis Treatment Market Trends

    ID: MRFR/Pharma/2493-CR
    153 Pages
    Kinjoll Dey
    August 2017

    Halitosis Treatment Market Research Report Information By Indication (Respiratory, Liver, Kidney, Gastrointestinal, Systemic, and Others), By Diagnostic Tests (Halimeter, Gas Chromatography, BANA Test, Β-Galactosidase Activity Assay, and Others), By Drug Treatment (Antacids, Antiseptics, Ranitidine, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market ...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Halitosis Treatment Market Infographic
    Purchase Options

    Market Trends

    Key Emerging Trends in the Halitosis Treatment Market

    In recent years, there has been a significant change in the approach to healthcare. Instead of solely focusing on treating illnesses after they occur, there is now a greater emphasis on preventing them in the first place. This shift is particularly evident in dentistry, where the focus is not just on fixing dental issues but also on preventing them from arising.

    One common concern that brings people to dental clinics is halitosis, or bad breath, which ranks as the third most frequent oral condition. The management of oral health has become more proactive, involving simple yet effective measures. These measures include adopting a healthy diet, maintaining good oral hygiene practices, and using oral health products such as mouthwashes, mouth sprays, and antibacterial toothpastes. Additionally, there is a growing recognition of the importance of education and awareness programs in addressing the social issue of bad breath.

    The spotlight on oral health has expanded in recent years, with increased awareness about the causes of various periodontal conditions. This shift from a focus on diagnosis to a more comprehensive approach to oral health reflects a broader trend in healthcare towards preventive care.

    A noteworthy development in the field of disease diagnosis comes from the Korea Advanced Institute of Science and Technology (KAIST). Researchers at KAIST have created diagnostic sensors utilizing protein-encapsulated nanocatalysts. These sensors have the capability to diagnose diseases through the analysis of exhaled breath. The technology operates on a breath pattern recognition platform, allowing for the early monitoring of diseases by identifying patterns of biomarker gases in breath.

    One of the significant applications of this technology is in the analysis of gaseous compounds related to various health conditions, including halitosis, lung cancer, and type 1 diabetes mellitus. By examining the breath, the sensors can detect specific patterns associated with these conditions, enabling early diagnosis and intervention.

    This innovation marks a significant step forward in the field of medical diagnostics. The ability to diagnose diseases through breath analysis offers a non-invasive and potentially more accessible method compared to traditional diagnostic procedures. This is particularly crucial for conditions like lung cancer and diabetes, where early detection can significantly impact treatment outcomes.

    In conclusion, the shift from a focus on diagnosis to a more proactive approach in healthcare is evident in the field of dentistry, where preventive measures are gaining prominence. Simultaneously, advancements in diagnostic technology, such as the development of nanosensors for disease diagnosis, showcase the commitment to early detection and intervention. These developments collectively contribute to a healthcare landscape that places a greater emphasis on managing health proactively and preventing diseases before they take hold.

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    What is the projected growth of the Halitosis Treatment market?

    The Halitosis Treatment market is the expected increase in total market value of 14.7 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

    What is the size of the Halitosis Treatment market?

    Halitosis Treatment market size was valued at approximately 4.89 billion USD in 2024. This figure will reach 14.7 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

    What is the CAGR of the Halitosis Treatment market?

    Halitosis Treatment market is expected to grow at a CAGR of 10.52% between 2025 and 2035.

    How much will the Halitosis Treatment market be worth by 2035?

    Halitosis Treatment market is expected to be worth of 14.7 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

    How will the Halitosis Treatment market perform over the next 10 years?

    Over the next 10 years the Halitosis Treatment market is expected to shift from usd billion 4.89 to 14.7 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

    Which region held the largest market share in the Halitosis Treatment market?

    North America had the largest share in the market

    Market Summary

    The Global Halitosis Treatment Market is projected to grow significantly from 4.89 USD Billion in 2024 to 14.70 USD Billion by 2035.

    Key Market Trends & Highlights

    Halitosis Treatment Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 10.54% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 14.7 USD Billion, indicating robust growth potential.
    • in 2024, the market is valued at 4.89 USD Billion, reflecting the current demand for halitosis treatments.
    • Growing adoption of innovative oral hygiene products due to increasing awareness of oral health is a major market driver.

    Market Size & Forecast

    2024 Market Size 4.89 (USD Billion)
    2035 Market Size 14.70 (USD Billion)
    CAGR (2025-2035) 10.52%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Colgate-Palmolive Company, All USA Partners LLC, Dr. Harold Katz, LLC, Rowpar Pharmaceuticals, Inc., Abbott, Listerine, AstraZeneca

    Market Trends

    Growing treatment is driving the market growth

    Market CAGR for halitosis treatment is being driven by the rising treatment. Further factors driving the market's expansion include the increased incidence of periodontal disorders, rising alcohol and tobacco usage, tonsillitis, and inflammation of the nose, throat, and sinuses. Halitosis is believed to be the third most prevalent cause for seeing a dentist, after periodontal disease and dental caries, according to a study titled "The Prevalence and Determinant Factors of Oral Halitosis in Northwest Ethiopia: A Cross-Sectional Study" released by Dovepress in 2021. Between 22% and 50% of individuals worldwide reported having halitosis.

    As a result, a key element anticipated to influence halitosis diagnosis and therapy shortly is the rising incidence of the condition worldwide.

    Additionally, gum (periodontal) disease, closely related to halitosis, may show warning signs such as chronic foul breath or an unpleasant taste in the mouth. The prevalence of total periodontitis and stage III/IV periodontitis was 85.4% and 48.5%, respectively, according to a study titled "Periodontal Disease Prevalence, Extent, and Risk Associations in Untreated Individuals" that was released in January 2022 by the AAP and the EFP. 78.4% and 31.1%, respectively, of people had moderate-to-severe periodontitis, according to the CDC/AAP. Therefore, it is anticipated that the rising frequency of periodontal disorders will propel market expansion during the study period.

    Halitosis is a widespread problem worldwide where severe instances only affect 5% of the population, but intermediate cases are common. The market is growing as the number of persons with halitosis increases and public knowledge of the condition and its treatment increases. In the US, almost 80 million people spend more than USD 10.75 billion yearly on dental care items. Thus, driving the Halitosis Treatment market revenue.

    The increasing awareness of oral hygiene and the rising prevalence of halitosis among the global population suggest a growing demand for effective treatment options in the halitosis treatment market.

    Centers for Disease Control and Prevention (CDC)

    Halitosis Treatment Market Market Drivers

    Growth of the Dental Care Sector

    The expansion of the dental care sector is significantly influencing the Global Halitosis Treatment Market Industry. As more individuals prioritize regular dental check-ups and preventive care, the likelihood of halitosis being diagnosed and treated increases. Dental professionals are increasingly incorporating discussions about bad breath into routine consultations, thereby raising awareness among patients. This proactive approach not only aids in early detection but also encourages the use of specialized products designed to combat halitosis. The synergy between dental care and halitosis treatment is likely to foster market growth, as consumers become more engaged in their oral health management.

    Innovations in Treatment Options

    Innovative advancements in treatment options for halitosis are propelling the Global Halitosis Treatment Market Industry forward. The introduction of new formulations, such as mouthwashes, sprays, and lozenges specifically designed to combat bad breath, is attracting consumer interest. For instance, products containing active ingredients like zinc compounds and essential oils are gaining popularity due to their effectiveness in neutralizing odor-causing bacteria. Furthermore, the development of personalized oral care solutions, which cater to individual needs, is likely to enhance consumer satisfaction and loyalty. This trend suggests a robust growth trajectory for the market, with a projected CAGR of 10.54% from 2025 to 2035.

    Rising Awareness of Oral Hygiene

    The increasing awareness regarding oral hygiene and its direct correlation with halitosis is a significant driver for the Global Halitosis Treatment Market Industry. Educational campaigns by dental associations and health organizations emphasize the importance of maintaining oral health, thereby encouraging consumers to seek effective treatments for bad breath. As individuals become more informed about the causes of halitosis, including poor dental care and certain medical conditions, the demand for specialized products and treatments is likely to rise. This heightened awareness is expected to contribute to the market's growth, with projections indicating a market value of 4.89 USD Billion in 2024.

    Consumer Demand for Natural Products

    The growing consumer preference for natural and organic products is shaping the Global Halitosis Treatment Market Industry. Many individuals are becoming more health-conscious and are seeking treatments that align with their values regarding sustainability and natural ingredients. This trend is evident in the rising popularity of mouthwashes and sprays made from herbal extracts and essential oils, which are perceived as safer alternatives to synthetic products. As manufacturers respond to this demand by developing natural formulations, the market is likely to witness an increase in product offerings. This shift towards natural solutions may further enhance the overall growth of the halitosis treatment market.

    Increasing Prevalence of Oral Diseases

    The rising prevalence of oral diseases, such as periodontal disease and dry mouth, is a crucial factor driving the Global Halitosis Treatment Market Industry. These conditions often lead to halitosis, prompting individuals to seek effective treatments. According to health statistics, a significant portion of the global population experiences some form of oral disease, which can exacerbate bad breath. As healthcare providers focus on preventive care and treatment options, the demand for halitosis solutions is expected to surge. This trend is indicative of a broader public health concern, with the market anticipated to reach 14.7 USD Billion by 2035, reflecting the urgent need for effective interventions.

    Market Segment Insights

    Halitosis Treatment Indication Insights

    Based on indication, the Halitosis Treatment market segmentation includes respiratory, liver, kidney,

    gastrointestinal,

    systemic, and others. The liver segment dominated the market, accounting for 35% of market revenue. Trimethylamine is more prevalent in cirrhotic patients, which leads to bad breath. One of the odd symptoms of fatty liver disease is "breath of the dead." The Fetor hepaticus, often known as the breath of the dead, is a lingering odor that differs from typical breath. Hepatitis and liver failure are intimately connected to fetor hepaticus. 

    Organ-related bad breath is typically caused by a sickness or food that interacts with blood levels and generates an odor. Since liver illnesses and bad breath are frequently linked, the rise in liver diseases is anticipated to accelerate the segment's growth throughout the projected period.

    Halitosis Treatment Diagnostic Tests Insights

    Based on diagnostic tests, the Halitosis Treatment market segmentation includes an altimeter, gas

    chromatography

    , BANA test, and Β-galactosidase activity assay. The BANA test segment dominated the market. The BANA test assesses the proteolytic activity of certain oral anaerobes that contribute to oral malodor. It refers to the enzymatic breakdown of [N-benzoyl-dL-arginine-2-napthylamide]. Treponema denticola, Prophyromona gingivitis, and Bacteroides forsythias (Red complex) are a few bacteria that create waste products that are highly odiferous and, as a result, contribute to foul breath. The N-benzoyl enzyme is destroyed when a patient's saliva sample containing these bacteria is added to the BANA testing chemical. The test substance changes color due to this biodegradation, indicating a successful response.

    Halitosis Treatment Drug Treatment Insights

    The Halitosis Treatment market segmentation, based on Drug Treatment, includes antacids, antiseptics, ranitidine, and others. The antacids generated the most income. Antacids are frequently used since they are affordable and help to reduce the discomfort, irritation, edema, and inflammation brought on by heartburn. Additionally, several product advancements, such as creating powerful and safe raft-forming antacids that offer improved efficacy and a longer duration of action, are boosting the market's expansion. The market is expected to develop due to the increasing use of chewable tablets in various flavors that are convenient to store, deliver the right dosage, and enhance patient adherence.

    Figure 1: Halitosis Treatment Market, by Drug Treatment, 2022 & 2032 (USD Billion)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Get more detailed insights about Halitosis Treatment Market Research Report- Forecast till 2032

    Regional Insights

    By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Halitosis Treatment market area will dominate this market due to an increase in periodontal disorders, a rise in halitosis prevalence, and increased general knowledge of the condition and its treatment options.

    Further, the major countries studied in the market report are The US, Canada, the UK, Italy, Spain, China, Japan, India, German, France, Australia, South Korea, and Brazil.

    Figure 2: HALITOSIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

     

    HALITOSIS TREATMENT MARKET SHARE BY REGION 2022 Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe has the second-largest market share for Halitosis Treatment. Due to rising oral hygiene awareness among people and rising diagnostic and therapeutic options for treating foul breath in several regional nations, the increasing prevalence of chronic illnesses like diabetes, respiratory conditions, and renal or liver failure with the growing population. Growing older adults with various conditions also contribute to the market's expansion. Furthermore, the German Halitosis Treatment market dominated, while the UK Halitosis Treatment market grew fastest in Europe.

    From 2023 to 2032, the Asia-Pacific Halitosis Treatment Market will develop at the quickest CAGR. A rise in knowledge about halitosis and the treatments available to cure it. Additionally, rising consumer desire for novel dental care products impacts market expansion. The region's residents make significant financial investments in healthcare, particularly dental care. Future growth of the market is predicted. Furthermore, China's Halitosis Treatment market had the highest market share, whereas India's Halitosis Treatment market was the Asia-Pacific region's fastest growing.

    Key Players and Competitive Insights

    Leading market companies are extensively spending R&D on increasing their product lines, which will help the Halitosis Treatment market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Halitosis Treatment industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.

    Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Halitosis Treatment industry to serve clients and expand the market sector. The Halitosis Treatment industry has provided some of the most important benefits recently. Church & Dwight., Colgate-Palmolive, and other major companies in the Halitosis Treatment market are aiming to enhance market demand by investing in research and development activities

    American consumer goods corporation Colgate-Palmolive has its main office on Park Avenue in Midtown Manhattan, New York City. Production, distribution, and provision of domestic, health, personal care, and veterinary items are the company's areas of expertise. The biggest manufacturer of soap and detergent in the world, Procter & Gamble (P&G), has long been a rival of Colgate-Palmolive. Following World War II, P&G launched their Tide laundry detergent, which attracted thousands of customers away from Colgate's soaps. When P&G introduced fluoride to their toothpaste, Colgate lost its top spot in the market (Colgate has subsequently reclaimed the top sales spot).

    In May 2021, In the United States, Colgate's Hello Products debuted fresh, natural, and eco-friendly oral care items like a reusable toothbrush, floss flavored with peppermint oil and coconut oil, tablets that freshen breath, and mouthwashes.

    The market leader in home and personal care goods is Church & Dwight. ARM & HAMMER, Batiste, OxiClean, Trojan, XTRA, Nair, First Response, Spinbrush, Orajel, vita fusion, Li'l Critters, Water Pik, FLAWLESS, Zicam, and TheraBreath are just a few of our internationally recognized brands. They were established in 1846, operate internationally, and are included in the S&P 500. At Church & Dwight, they fuel people's daily lives by offering high-quality, cost-effective consumer goods. Where impact meets ambition is here. They are proud to be experts in our fields. Their team of highly skilled individuals innovates and concentrates on innovative methods.

    In November 2021, Church & Dwight Co., Inc. signed a legally binding contract to buy the TheraBreath name. TheraBreath is the second most popular brand of alcohol-free mouthwash in the US. Therefore, these advancements will probably help the market in North America flourish.

    Key Companies in the Halitosis Treatment Market market include

    Industry Developments

    • Q2 2024: TheraBreath Launches New Oral Rinse Targeting Halitosis TheraBreath announced the launch of a new oral rinse specifically formulated to target halitosis, expanding its product portfolio in the oral care market.
    • Q2 2024: GSK Introduces Sensodyne Fresh Breath Toothpaste for Halitosis Relief GlaxoSmithKline launched Sensodyne Fresh Breath Toothpaste, designed to address halitosis while providing sensitivity relief, marking a new addition to its oral health product line.
    • Q3 2024: Oral Science Announces Partnership with Dental Clinics for Halitosis Treatment Program Oral Science entered into a partnership with a network of dental clinics to implement a specialized halitosis treatment program using its proprietary products.
    • Q3 2024: Colgate-Palmolive Expands Manufacturing Facility for Halitosis Treatment Products Colgate-Palmolive announced the expansion of its manufacturing facility in New Jersey to increase production capacity for its halitosis treatment product line.
    • Q4 2024: FDA Approves New Prescription Mouthwash for Chronic Halitosis The U.S. FDA approved a new prescription mouthwash developed for chronic halitosis, marking a regulatory milestone for advanced oral care therapeutics.
    • Q4 2024: Johnson & Johnson Acquires BreathRx Brand to Strengthen Halitosis Portfolio Johnson & Johnson completed the acquisition of the BreathRx brand, enhancing its portfolio of products targeting halitosis and oral malodor.
    • Q1 2025: LISTERINE Launches Advanced Formula for Bad Breath in Asia-Pacific LISTERINE introduced an advanced mouthwash formula targeting bad breath in the Asia-Pacific region, aiming to capture growing demand for halitosis solutions.
    • Q1 2025: Oral Care Startup BreathWell Raises $15M Series A to Develop Halitosis Diagnostic Device BreathWell, a health tech startup, secured $15 million in Series A funding to accelerate development of its non-invasive halitosis diagnostic device.
    • Q2 2025: Procter & Gamble Announces Strategic Partnership with Dental Chain for Halitosis Education Procter & Gamble formed a strategic partnership with a major dental chain to launch a halitosis education and treatment initiative across multiple clinics.
    • Q2 2025: FreshBreath Technologies Files for IPO to Fund Halitosis Treatment Product Expansion FreshBreath Technologies filed for an initial public offering, aiming to raise capital for expanding its halitosis treatment product line and global distribution.
    • Q3 2025: Dentek Unveils New Tongue Cleaner for Halitosis Prevention Dentek launched a new tongue cleaner designed to help prevent halitosis, broadening its oral hygiene product offerings.
    • Q3 2025: Novartis Receives European Approval for Halitosis Treatment Tablet Novartis received regulatory approval in Europe for its new tablet indicated for the treatment of halitosis, expanding its presence in the oral care therapeutics market.

    Future Outlook

    Halitosis Treatment Market Future Outlook

    The Halitosis Treatment Market is projected to grow at a 10.52% CAGR from 2025 to 2035, driven by increasing awareness of oral hygiene, technological advancements, and rising demand for effective treatments.

    New opportunities lie in:

    • Develop innovative, natural-based halitosis treatments targeting health-conscious consumers.
    • Leverage telehealth platforms for remote consultations and personalized treatment plans.
    • Expand distribution channels through e-commerce to reach a broader audience globally.

    By 2035, the Halitosis Treatment Market is expected to be robust, reflecting significant advancements and consumer engagement.

    Market Segmentation

    Halitosis Treatment Regional Outlook

    North America
    • US
    • Canada

    Halitosis Treatment Indication Outlook

    • Respiratory
    • Liver
    • Kidney
    • Gastrointestinal
    • Systemic
    • Others

    Halitosis Treatment Diagnostic Tests Outlook

    • Halimeter
    • Gas Chromatography
    • BANA Test
    • Β-Galactosidase Activity Assay
    • Others

    Halitosis Treatment Drug Treatment Outlook

    • Antacids
    • Antiseptics
    • Ranitidine
    • Others

    Report Scope

    Attribute/Metric Details
    Market Size 2024 USD 4.89 Billion
    Market Size 2035 14.70 (Value (USD Billion))
    Compound Annual Growth Rate (CAGR) 10.52% (2025 - 2035)
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2019- 2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Type, Drug Treatment, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Colgate-Palmolive Company (U.S), All USA Partners LLC (U.S), Dr. Harold Katz, LLC (U.S), Rowpar Pharmaceuticals, Inc. (U.S), Abbott (U.S), Listerine (U.S), AstraZeneca (U.S)
    Key Market Opportunities Dental Health Care Products
    Key Market Dynamics Rising incidence of periodontal disease
    Market Size 2025 5.40 (Value (USD Billion))

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What is the projected growth of the Halitosis Treatment market?

    The Halitosis Treatment market is the expected increase in total market value of 14.7 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

    What is the size of the Halitosis Treatment market?

    Halitosis Treatment market size was valued at approximately 4.89 billion USD in 2024. This figure will reach 14.7 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

    What is the CAGR of the Halitosis Treatment market?

    Halitosis Treatment market is expected to grow at a CAGR of 10.52% between 2025 and 2035.

    How much will the Halitosis Treatment market be worth by 2035?

    Halitosis Treatment market is expected to be worth of 14.7 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

    How will the Halitosis Treatment market perform over the next 10 years?

    Over the next 10 years the Halitosis Treatment market is expected to shift from usd billion 4.89 to 14.7 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

    Which region held the largest market share in the Halitosis Treatment market?

    North America had the largest share in the market

    1. REPORT PROLOGUE
    2. MARKET INTRODUCTION
      1. INTRODUCTION 17
      2. SCOPE OF STUDY 17
      3. RESEARCH OBJECTIVE 17
        1. ASSUMPTIONS 18
      4. 2.4
      5. ASSUMPTIONS & LIMITATIONS 18
      6. 2.4.2
      7. LIMITATIONS 18
      8. MARKET STRUCTURE 19
    3. RESEARCH METHODOLOGY: HALITOSIS
      1. MARKET
      2. RESEARCH PROCESS 20
      3. MARKET SIZE ESTIMATION 22
        1. MARKET SHARE ANALYSIS 23
      4. FORECAST MODEL 24
    4. MARKER
      1. DYNAMICS
      2. DRIVERS 25
        1. RISING PREVALENCE OF PERIODONTAL DISEASES
        2. GERIATRIC POPULATION 25
        3. AVAILABILITY OF WIDE
        4. INCREASING PREVALENCE OF CHRONIC DISEASES
      3. 25
      4. RANGE OF PRODUCTS 25
      5. 25
      6. RESTRAINTS 26
        1. LACK OF AWARENESS ABOUT HALITOSIS
        2. ALTERNATIVE TREATMENT 26
      7. AND ITS TREATMENT 26
      8. OPPORTUNITIES
        1. TECHNOLOGICAL ADVANCEMENT 26
      9. 26
      10. MEGA TRENDS 26
        1. SHIFT FROM DIAGNOSIS TO MANAGEMENT 26
        2. NANO SENSOR
      11. FOR DISEASE DIAGNOSIS 27
      12. MACROECONOMIC INDICATORS 27
    5. MARKET
    6. FACTOR ANALYSIS
      1. PORTER’S FIVE FORCES MODEL 28
        1. BARGAINING
        2. BARGAINING POWER OF BUYERS 29
        3. THREAT OF SUBSTITUTES 29
      2. POWER OF SUPPLIERS 29
      3. 5.1.3
      4. THREAT OF NEW ENTRANTS 29
      5. 5.1.5
      6. INTENSITY OF RIVALRY 29
      7. VALUE CHAIN ANALYSIS 30
        1. MANUFACTURING 30
        2. DISTRIBUTION &
        3. POST-SALES SERVICES 31
      8. 5.2.1
      9. R&D 30
      10. SALES 31
      11. PRICING ANALYSIS
      12. 32
      13. INVESTMENT OPPORTUNITY ANALYSIS 33
    7. HALITOSIS TREATMENT
    8. MARKET, BY TYPE
      1. INTRODUCTION 34
      2. PATHOLOGIC HALITOSIS 36
      3. OTHER HALITOSIS 37
    9. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. INTRODUCTION 38
      2. RESPIRATORY DISORDERS 39
      3. LIVER
      4. DISORDERS 41
      5. KIDNEY DISORDER 42
      6. GASTROINTESTINAL DISORDERS
      7. 43
      8. SYSTEMIC DISORDERS 44
    10. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC
      1. TEST
      2. INTRODUCTION 45
      3. HALIMETER 46
      4. GAS CHROMATOGRAPHY
      5. 47
      6. BANA TEST 48
      7. B- GALACTOSIDASE ACTIVITY ASSAY 49
      8. OTHER TESTS 50
    11. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. INTRODUCTION 51
      2. ANTACIDS 53
      3. ANTISEPTICS 54
      4. RANITIDINE 55
      5. OTHER TREATMENTS 56
    12. GLOBAL HALITOSIS
    13. TREATMENT MARKET, BY REGION
      1. INTRODUCTION 57
      2. AMERICAS 58
    14. HALITOSIS TREATMENT MARKET, BY TYPE
    15. HALITOSIS TREATMENT MARKET, BY INDICATION
    16. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
      1. HALITOSIS TREATMENT MARKET,
      2. BY DRUG TREATMENT
      3. HALITOSIS TREATMENT MARKET, BY
      4. TYPE
    17. U.S. 63
    18. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS TREATMENT MARKET,
      2. BY DIAGNOSTIC TEST
    19. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. 10.2.2
      2. CANADA 66
    20. HALITOSIS TREATMENT MARKET, BY TYPE
      1. HALITOSIS TREATMENT MARKET,
      2. BY INDICATION
    21. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
      1. HALITOSIS
    22. TREATMENT MARKET, BY DRUG TREATMENT
      1. HALITOSIS
    23. SOUTH AMERICA 69
    24. TREATMENT MARKET, BY TYPE
    25. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS
    26. TREATMENT MARKET, BY DIAGNOSTIC TEST
    27. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. EUROPE 73
    28. HALITOSIS TREATMENT MARKET, BY TYPE
      1. HALITOSIS TREATMENT
    29. MARKET, BY INDICATION
    30. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
      1. HALITOSIS
    31. TREATMENT MARKET, BY DRUG TREATMENT
      1. HALITOSIS
    32. GERMANY 77
    33. TREATMENT MARKET, BY TYPE
    34. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS
    35. TREATMENT MARKET, BY DIAGNOSTIC TEST
    36. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
    37. FRANCE 80
    38. HALITOSIS TREATMENT MARKET, BY TYPE
      1. HALITOSIS
    39. TREATMENT MARKET, BY INDICATION
    40. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
    41. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. HALITOSIS
    42. UK 83
    43. TREATMENT MARKET, BY TYPE
    44. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS
    45. TREATMENT MARKET, BY DIAGNOSTIC TEST
    46. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
    47. ITALY 86
    48. HALITOSIS TREATMENT MARKET, BY TYPE
      1. HALITOSIS
    49. TREATMENT MARKET, BY INDICATION
    50. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
    51. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. HALITOSIS
    52. SPAIN 89
    53. TREATMENT MARKET, BY TYPE
    54. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS
    55. TREATMENT MARKET, BY DIAGNOSTIC TEST
    56. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
    57. EASTERN EUROPE 92
    58. HALITOSIS TREATMENT MARKET, BY TYPE
      1. HALITOSIS
    59. TREATMENT MARKET, BY INDICATION
    60. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
    61. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. ASIA PACIFIC 96
    62. HALITOSIS TREATMENT MARKET, BY TYPE
    63. HALITOSIS TREATMENT MARKET, BY INDICATION
    64. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
      1. HALITOSIS TREATMENT MARKET,
      2. BY DRUG TREATMENT
      3. HALITOSIS TREATMENT MARKET, BY
      4. TYPE
    65. JAPAN 100
    66. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS TREATMENT MARKET,
      2. BY DIAGNOSTIC TEST
    67. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. 10.4.2
      2. CHINA 103
    68. HALITOSIS TREATMENT MARKET, BY TYPE
      1. HALITOSIS TREATMENT MARKET,
      2. BY INDICATION
    69. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
      1. HALITOSIS
    70. TREATMENT MARKET, BY DRUG TREATMENT
      1. HALITOSIS TREATMENT
    71. INDIA 106
    72. MARKET, BY TYPE
    73. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS TREATMENT
    74. MARKET, BY DIAGNOSTIC TEST
    75. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
    76. AUSTRALIA 109
    77. HALITOSIS TREATMENT MARKET, BY TYPE
      1. HALITOSIS
    78. TREATMENT MARKET, BY INDICATION
    79. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
    80. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. 112
    81. REPUBLIC OF KOREA
    82. HALITOSIS TREATMENT MARKET, BY TYPE
      1. HALITOSIS TREATMENT MARKET, BY
      2. INDICATION
    83. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
      1. HALITOSIS TREATMENT
    84. MARKET, BY DRUG TREATMENT
      1. HALITOSIS
    85. REST OF ASIA PACIFIC 115
    86. TREATMENT MARKET, BY TYPE
    87. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS
    88. TREATMENT MARKET, BY DIAGNOSTIC TEST
    89. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. MIDDLE EAST & AFRICA 118
    90. HALITOSIS TREATMENT MARKET, BY TYPE
    91. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS TREATMENT MARKET, BY
      2. DIAGNOSTIC TEST
    92. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
      1. 10.5.1
      2. MIDDLE EAST 122
    93. HALITOSIS TREATMENT MARKET, BY TYPE
      1. HALITOSIS TREATMENT
    94. MARKET, BY INDICATION
    95. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
      1. HALITOSIS
    96. TREATMENT MARKET, BY DRUG TREATMENT
      1. HALITOSIS
    97. AFRICA 125
    98. TREATMENT MARKET, BY TYPE
    99. HALITOSIS TREATMENT MARKET, BY INDICATION
      1. HALITOSIS
    100. TREATMENT MARKET, BY DIAGNOSTIC TEST
    101. HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
    102. COMPETITIVE LANDSCAPE
      1. INTRODUCTION 129
      2. COMPANY SHARE
      3. ANALYSIS 130
      4. ABBOTT 131
        1. COMPANY OVERVIEW 131
        2. PRODUCT/BUSINESS SEGMENT OVERVIEW 131
        3. FINANCIAL
        4. KEY DEVELOPMENTS 133
        5. SWOT ANALYSIS
      5. UPDATES 131
      6. 133
      7. ALL USA PARTNERS LLC 134
        1. COMPANY OVERVIEW
        2. PRODUCT/BUSINESS SEGMENT OVERVIEW 134
        3. FINANCIAL
        4. KEY DEVELOPMENTS 134
        5. SWOT ANALYSIS
      8. 134
      9. UPDATES 134
      10. 135
      11. ASTRAZENECA 136
        1. COMPANY OVERVIEW 136
        2. PRODUCT/BUSINESS SEGMENT OVERVIEW 136
        3. FINANCIAL OVERVIEW
        4. KEY DEVELOPMENT 137
        5. SWOT ANALYSIS 138
      12. 136
      13. COLGATE-PALMOLIVE COMPANY 139
        1. COMPANY OVERVIEW 139
        2. PRODUCT/BUSINESS SEGMENT OVERVIEW 139
        3. FINANCIAL
        4. KEY DEVELOPMENTS 140
        5. SWOT ANALYSIS
      14. UPDATES 139
      15. 141
      16. DR. HAROLD KATZ, LLC 142
        1. COMPANY OVERVIEW
        2. PRODUCT/BUSINESS SEGMENT OVERVIEW 142
        3. FINANCIAL
        4. KEY DEVELOPMENTS 142
        5. SWOT ANALYSIS
      17. 142
      18. UPDATES 142
      19. 143
      20. LISTERINE (PART OF JOHNSON & JOHNSON) 144
        1. PRODUCT/BUSINESS SEGMENT OVERVIEW 144
        2. FINANCIAL UPDATES 144
        3. KEY DEVELOPMENTS 145
        4. SWOT ANALYSIS 146
      21. 11.8.1
      22. COMPANY OVERVIEW 144
      23. ROWPAR PHARMACEUTICALS, INC. 147
        1. COMPANY OVERVIEW 147
        2. PRODUCT/BUSINESS SEGMENT OVERVIEW
        3. FINANCIAL UPDATES 147
        4. KEY DEVELOPMENTS 147
        5. SWOT ANALYSIS 148
      24. 147
    103. MRFR CONCLUSION
      1. KEY FINDINGS
        1. FROM CEO’S VIEW POINT 149
        2. UNMET NEEDS
      2. 149
      3. 149
      4. KEY COMPANIES TO WATCH 149
    104. APPENDIX
      1. DISCUSSION
      2. BLUE PRINT 150
      3. REFERENCES 152
    105. List of Tables
      1. TABLE
    106. GLOBAL HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 34
    107. GLOBAL HALITOSIS TREATMENT MARKET FOR PATHOLOGIC HALITOSIS, BY REGION,
    108. GLOBAL HALITOSIS TREATMENT MARKET
      1. FOR OTHER HALITOSIS, BY REGION, 2023-2030 (USD MILLION) 37
    109. GLOBAL
    110. HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 38
      1. TABLE
    111. GLOBAL HALITOSIS TREATMENT MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023-2030
      1. (USD MILLION) 40
    112. GLOBAL HALITOSIS TREATMENT MARKET FOR LIVER
      1. DISORDERS, BY REGION, 2023-2030 (USD MILLION) 41
    113. GLOBAL HALITOSIS
    114. TREATMENT MARKET FOR KIDNEY DISORDER, BY REGION, 2023-2030 (USD MILLION) 42
    115. GLOBAL HALITOSIS TREATMENT MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION,
    116. GLOBAL HALITOSIS TREATMENT MARKET
      1. FOR SYSTEMIC DISORDERS, BY REGION, 2023-2030 (USD MILLION) 44
      2. TABLE 10
    117. GLOBAL HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 45
    118. GLOBAL HALITOSIS TREATMENT MARKET FOR HALIMETER, BY REGION, 2023-2030
      1. (USD MILLION) 47
    119. GLOBAL HALITOSIS TREATMENT MARKET FOR GAS CHROMATOGRAPHY,
      1. BY REGION, 2023-2030 (USD MILLION) 48
    120. GLOBAL HALITOSIS TREATMENT
    121. MARKET FOR BANA TEST, BY REGION, 2023-2030 (USD MILLION) 48
      1. TABLE 14
    122. GLOBAL HALITOSIS TREATMENT MARKET FOR B- GALACTOSIDASE ACTIVITY ASSAY, BY REGION,
    123. GLOBAL HALITOSIS TREATMENT MARKET
      1. FOR OTHER TESTS, BY REGION, 2023-2030 (USD MILLION) 50
    124. GLOBAL
    125. HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 51
      1. TABLE
    126. GLOBAL HALITOSIS TREATMENT MARKET FOR ANTACIDS, BY REGION, 2023-2030 (USD MILLION)
      1. 53
    127. GLOBAL HALITOSIS TREATMENT MARKET FOR ANTISEPTICS, BY REGION,
    128. GLOBAL HALITOSIS TREATMENT MARKET
      1. FOR RANITIDINE, BY REGION, 2023-2030 (USD MILLION) 55
    129. GLOBAL
    130. HALITOSIS TREATMENT MARKET FOR OTHER TREATMENT, BY REGION, 2023-2030 (USD MILLION)
      1. 56
    131. GLOBAL HALITOSIS TREATMENT MARKET, BY REGION, 2023-2030 (USD
      1. MILLION) 57
    132. AMERICAS HALITOSIS TREATMENT MARKET, BY COUNTRY,
    133. AMERICAS HALITOSIS TREATMENT MARKET,
      1. BY TYPE, 2023-2030 (USD MILLION) 60
    134. AMERICAS HALITOSIS TREATMENT
    135. MARKET, BY INDICATION, 2023-2030 (USD MILLION) 60
    136. AMERICAS HALITOSIS
    137. TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 61
      1. TABLE
    138. AMERICAS HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 62
    139. U.S. HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
      1. 63
    140. U.S. HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030
      1. (USD MILLION) 64
    141. U.S. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC
      1. TEST, 2023-2030 (USD MILLION) 65
    142. U.S. HALITOSIS TREATMENT MARKET,
      1. BY TREATMENT, 2023-2030 (USD MILLION) 65
    143. CANADA HALITOSIS TREATMENT
    144. MARKET, BY TYPE, 2023-2030 (USD MILLION) 66
    145. CANADA HALITOSIS
    146. TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 67
      1. TABLE 33
    147. CANADA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 68
    148. CANADA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD
      1. MILLION) 68
    149. SOUTH AMERICA HALITOSIS TREATMENT MARKET, BY TYPE,
    150. SOUTH AMERICA HALITOSIS TREATMENT
    151. MARKET, BY INDICATION, 2023-2030 (USD MILLION) 70
    152. SOUTH AMERICA
    153. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 71
    154. SOUTH AMERICA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD
      1. MILLION) 71
    155. EUROPE HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023-2030
      1. (USD MILLION) 73
    156. EUROPE HALITOSIS TREATMENT MARKET, BY TYPE,
    157. EUROPE HALITOSIS TREATMENT MARKET,
      1. BY INDICATION, 2023-2030 (USD MILLION) 75
    158. EUROPE HALITOSIS TREATMENT
    159. MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 76
    160. EUROPE
    161. HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 76
      1. TABLE
    162. GERMANY HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 77
    163. GERMANY HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION)
      1. 78
    164. GERMANY HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030
      1. (USD MILLION) 79
    165. GERMANY HALITOSIS TREATMENT MARKET, BY TREATMENT,
    166. FRANCE HALITOSIS TREATMENT MARKET,
      1. BY TYPE, 2023-2030 (USD MILLION) 80
    167. FRANCE HALITOSIS TREATMENT
    168. MARKET, BY INDICATION, 2023-2030 (USD MILLION) 81
    169. FRANCE HALITOSIS
    170. TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 82
      1. TABLE
    171. FRANCE HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 82
    172. UK HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
      1. 83
    173. UK HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD
      1. MILLION) 84
    174. U.K. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST,
    175. UK HALITOSIS TREATMENT MARKET, BY
      1. TREATMENT, 2023-2030 (USD MILLION) 85
    176. ITALY HALITOSIS TREATMENT
    177. MARKET, BY TYPE, 2023-2030 (USD MILLION) 86
    178. ITALY HALITOSIS
    179. TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 87
      1. TABLE 58
    180. ITALY HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 88
    181. ITALY HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD
      1. MILLION) 88
    182. SPAIN HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030
      1. (USD MILLION) 89
    183. SPAIN HALITOSIS TREATMENT MARKET, BY INDICATION,
    184. SPAIN HALITOSIS TREATMENT MARKET,
      1. BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 91
    185. SPAIN HALITOSIS
    186. TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 91
    187. EASTERN
    188. EUROPE HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 92
    189. EASTERN EUROPE HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD
      1. MILLION) 93
    190. EASTERN EUROPE HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC
      1. TEST, 2023-2030 (USD MILLION) 94
    191. EASTERN EUROPE HALITOSIS TREATMENT
    192. MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 94
    193. ASIA PACIFIC
    194. HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 96
      1. TABLE
    195. ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 97
    196. ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030
      1. (USD MILLION) 98
    197. ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY
      1. DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 99
    198. ASIA PACIFIC HALITOSIS
    199. TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 99
    200. JAPAN
    201. HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 100
      1. TABLE
    202. JAPAN HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 101
    203. JAPAN HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030
      1. (USD MILLION) 102
    204. JAPAN HALITOSIS TREATMENT MARKET, BY TREATMENT,
    205. CHINA HALITOSIS TREATMENT MARKET,
      1. BY TYPE, 2023-2030 (USD MILLION) 103
    206. CHINA HALITOSIS TREATMENT
    207. MARKET, BY INDICATION, 2023-2030 (USD MILLION) 104
    208. CHINA HALITOSIS
    209. TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 105
      1. TABLE
    210. CHINA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 105
    211. INDIA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
      1. 106
    212. INDIA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030
      1. (USD MILLION) 107
    213. INDIA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC
      1. TEST, 2023-2030 (USD MILLION) 108
    214. INDIA HALITOSIS TREATMENT
    215. MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 108
    216. AUSTRALIA
    217. HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 109
      1. TABLE
    218. AUSTRALIA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION)
      1. 110
    219. AUSTRALIA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST,
    220. AUSTRALIA HALITOSIS TREATMENT MARKET,
      1. BY TREATMENT, 2023-2030 (USD MILLION) 111
    221. REPUBLIC OF KOREA
    222. HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 112
      1. TABLE
    223. REPUBLIC OF KOREA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION)
      1. 113
    224. REPUBLIC OF KOREA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC
      1. TEST, 2023-2030 (USD MILLION) 114
    225. REPUBLIC OF KOREA HALITOSIS
    226. TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 114
      1. TABLE 93
    227. REST OF ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION)
      1. 115
    228. REST OF ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY INDICATION,
    229. REST OF ASIA PACIFIC HALITOSIS TREATMENT
    230. MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 117
    231. REST
    232. OF ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
      1. 117
    233. MIDDLE EAST & AFRICA HALITOSIS TREATMENT MARKET, BY
      1. COUNTRY, 2023-2030 (USD MILLION) 118
    234. MIDDLE EAST & AFRICA
    235. HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 119
      1. TABLE
    236. MIDDLE EAST & AFRICA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030
      1. (USD MILLION) 120
    237. MIDDLE EAST & AFRICA HALITOSIS TREATMENT
    238. MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 121
    239. MIDDLE
    240. EAST & AFRICA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
      1. 121
    241. MIDDLE EAST HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030
      1. (USD MILLION) 122
    242. MIDDLE EAST HALITOSIS TREATMENT MARKET, BY
      1. INDICATION, 2023-2030 (USD MILLION) 123
    243. MIDDLE EAST HALITOSIS
    244. TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 124
      1. TABLE
    245. MIDDLE EAST HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION)
      1. 124
    246. AFRICA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD
      1. MILLION) 125
    247. AFRICA HALITOSIS TREATMENT MARKET, BY INDICATION,
    248. AFRICA HALITOSIS TREATMENT MARKET,
      1. BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 127
    249. AFRICA HALITOSIS
    250. TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 127
      1. TABLE 110
      2. ABBOTT: KEY DEVELOPMENTS 133
    251. ROWPAR PHARMACEUTICALS, INC.:
      1. KEY DEVELOPMENTS 147
    252. List of Figures
    253. GLOBAL HALITOSIS
    254. MARKET, BY TYPE, 2023 (%) 13
    255. GLOBAL HALITOSIS MARKET, BY INDICATION,
    256. GLOBAL HALITOSIS MARKET, BY DIAGNOSTIC TEST, 2023
      1. (%) 14
    257. GLOBAL HALITOSIS MARKET, BY TREATMENT, 2023 (%) 15
    258. GLOBAL HALITOSIS MARKET, BY REGION, 2023 (%) 16
      1. FIGURE
    259. GLOBAL HALITOSIS MARKET: MARKET STRUCTURE 19
    260. RESEARCH PROCESS
      1. 20
    261. MARKET ASSESMENT: TRAIGULATION APPROACH 21
      1. FIGURE
    262. GLOBAL HALITOSIS MARKET: FORECAST MODEL 24
    263. PORTERS FIVE FORCES
      1. MODEL 28
    264. VALUE CHAIN: HALITOSIS 30
    265. GLOBAL
    266. HALITOSIS TREATMENT MARKET, BY TYPE, 2023 & 2030 (USD MILLION) 35
      1. FIGURE
    267. GLOBAL HALITOSIS TREATMENT MARKET, BY INDICATION, 2023 & 2030 (USD MILLION)
      1. 39
    268. GLOBAL HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023
      1. & 2030 (USD MILLION) 46
    269. GLOBAL HALITOSIS TREATMENT MARKET,
      1. BY TREATMENT, 2023 & 2030 (USD MILLION) 52
    270. GLOBAL HALITOSIS
    271. TREATMENT MARKET, BY REGION, 2023 & 2030 (USD MILLION) 58
      1. FIGURE
    272. AMERICAS HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023 (%) 59
      1. FIGURE
    273. EUROPE HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023 (%) 74
      1. FIGURE
    274. ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023 (%) 97
      1. FIGURE
    275. MIDDLE EAST & AFRICA HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023 (%) 118
    276. GLOBAL HALITOSIS MARKET: COMPETITIVE LANDSCAPE 129
      1. FIGURE
    277. GLOBAL HALITOSIS MARKET: COMPANY SHARE ANALYSIS 130
    278. ABBOTT:
      1. RECENT FINANCIALS (USD MILLION) 131
    279. ABBOTT: GEOGRAPHICAL REVENUE,
    280. ABBOTT: SEGMENTAL REVENUE, 2023 (%) 132
    281. ABBOTT: SWOT ANALYSIS 133
    282. ALL USA PARTNERS LLC:
      1. SWOT ANALYSIS 135
    283. ASTRAZENECA: RECENT FINANCIAL 136
    284. ASTRAZENECA: OPERATING SEGMENTS 137
    285. ASTRAZENECA:
      1. GEOGRAPHICAL MIX 137
    286. ASTRAZENECA: SWOT ANALYSIS 138
    287. COLGATE-PALMOLIVE COMPANY: RECENT FINANCIALS (USD MILLION) 139
    288. COLGATE-PALMOLIVE COMPANY: GEOGRAPHICAL REVENUE, 2023 (%) 140
    289. COLGATE-PALMOLIVE COMPANY: SEGMENTAL REVENUE, 2023 (%) 140
    290. COLGATE-PALMOLIVE COMPANY: SWOT ANALYSIS 141
    291. DR.
      1. HAROLD KATZ, LLC: SWOT ANALYSIS 143
    292. LISTERINE: RECENT FINANCIALS
      1. (USD MILLION) 144
    293. LISTERINE: GEOGRAPHICAL REVENUE, 2023 (%)
      1. 145
    294. LISTERINE: SEGMENTAL REVENUE, 2023 (%) 145
      1. FIGURE
    295. LISTERINE: SWOT ANALYSIS 146
    296. ROWPAR PHARMACEUTICALS, INC.:
      1. SWOT ANALYSIS 148

    Market Segmentation

    Halitosis Treatment Indication Outlook (USD Billion, 2018-2032)

    • Respiratory
    • Liver
    • Kidney
    • Gastrointestinal
    • Systemic
    • Others

    Halitosis Treatment Diagnostic Tests Outlook (USD Billion, 2018-2032)

    • Halimeter
    • Gas Chromatography
    • BANA Test
    • Β-Galactosidase Activity Assay
    • Others

    Halitosis Treatment Drug Treatment Outlook (USD Billion, 2018-2032)

    • Antacids
    • Antiseptics
    • Ranitidine
    • Others

    Halitosis Treatment Regional Outlook (USD Billion, 2018-2032)

    • North America Outlook (USD Billion, 2018-2032)

      • North America Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • North America Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • North America Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • US Outlook (USD Billion, 2018-2032)

      • US Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • US Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • US Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • CANADA Outlook (USD Billion, 2018-2032)

      • CANADA Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • CANADA Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • CANADA Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
    • Europe Outlook (USD Billion, 2018-2032)

      • Europe Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Europe Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Europe Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • Germany Outlook (USD Billion, 2018-2032)

      • Germany Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Germany Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Germany Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • France Outlook (USD Billion, 2018-2032)

      • France Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • France Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • France Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • UK Outlook (USD Billion, 2018-2032)

      • UK Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • UK Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • UK Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • ITALY Outlook (USD Billion, 2018-2032)

      • ITALY Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • ITALY Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • ITALY Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • SPAIN Outlook (USD Billion, 2018-2032)

      • Spain Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Spain Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Spain Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • Rest Of Europe Outlook (USD Billion, 2018-2032)

      • Rest Of Europe Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Rest Of Europe Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Rest Of Europe Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
    • Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Asia-Pacific Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Asia-Pacific Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Asia-Pacific Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • China Outlook (USD Billion, 2018-2032)

      • China Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • China Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • China Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • Japan Outlook (USD Billion, 2018-2032)

      • Japan Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Japan Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Japan Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • India Outlook (USD Billion, 2018-2032)

      • India Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • India Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • India Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • Australia Outlook (USD Billion, 2018-2032)

      • Australia Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Australia Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Australia Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Rest of Asia-Pacific Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Rest of Asia-Pacific Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Rest of Asia-Pacific Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
    • Rest of the World Outlook (USD Billion, 2018-2032)

      • Rest of the World Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Rest of the World Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Rest of the World Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • Middle East Outlook (USD Billion, 2018-2032)

      • Middle East Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Middle East Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Middle East Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • Africa Outlook (USD Billion, 2018-2032)

      • Africa Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Africa Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Africa Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
      • Latin America Outlook (USD Billion, 2018-2032)

      • Latin America Halitosis Treatment by Indication
        • Respiratory
        • Liver
        • Kidney
        • Gastrointestinal
        • Systemic
        • Others
      • Latin America Halitosis Treatment by Diagnostic Tests
        • Halimeter
        • Gas Chromatography
        • BANA Test
        • Β-Galactosidase Activity Assay
        • Others
      • Latin America Halitosis Treatment by Drug Treatment
        • Antacids
        • Antiseptics
        • Ranitidine
        • Others
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions